Last year, many new multimedia features were added to the redesigned website, which includes a newsfeed, commentary, infographics, animations, video clips, health calculators and trackers, quizzes, as well as a drug interaction checker, pill identifier, and guide to pronunciation of medical terms.
Drug Channels' Adam Fein, CEO, after combing through the 658 pages released last week by the Centers for Medicare & Medicaid Services regarding the final rule governing Average Manufacturer Price under the Patient Protection and Affordable Care Act, outlined the seven ways this new rule will impact pharmacy. "Savor all of the bureaucratese for yourself in the oh-so-brief 658-page rule, known to the cool kids as CMS-2345-FC," Fein writes. His observations outline potential impacts including prescription reimbursement, pharmacy profits and channel strategies. (Read through to the end, and Fein provides a bonus five observations.) (Drug Channels)
The new indication comes just a few months after the FDA approved Botox to treat upper limb spasticity in two thumb muscles and six years after it was approved to treat upper limb spasticity in the elbow, wrist and fingers.